Editorial
doi: 10.1016/j.jtho.2024.03.004.
The Surgical Resection Difficulty From Neoadjuvant Chemoimmunotherapy Is Minimal and Neoadjuvant Therapy Should Be the Standard
Affiliations
- PMID: 38849166
- DOI: 10.1016/j.jtho.2024.03.004
Item in Clipboard
Editorial
The Surgical Resection Difficulty From Neoadjuvant Chemoimmunotherapy Is Minimal and Neoadjuvant Therapy Should Be the Standard
J Thorac Oncol.
2024 Jun.
Free article
No abstract available
Conflict of interest statement
Disclosure Dr. Dickhoff reports receiving research grants and consulting fees from AstraZeneca and Bristol Myers Squibb. Dr. Bahce reports receiving research grants and consulting fees from AstraZeneca, Bristol Myers Squibb, and Boehringer Ingelheim. Dr. Senan reports receiving research grants from AstraZeneca, ViewRay Inc., and Varian Medical Systems; and consulting fees from ViewRay Inc., AstraZeneca, and Merck Sharp & Dohme. The remaining authors declare no conflict of interest.
Similar articles
-
Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.Thorac Cancer. 2021 Oct;12(20):2796-2802. doi: 10.1111/1759-7714.14127. Epub 2021 Aug 30. Thorac Cancer. 2021. PMID: 34463034 Free PMC article.
-
Real-World Experience Favors a Neoadjuvant Strategy of Chemoimmunotherapy for Locoregionally Advanced NSCLC.Ann Thorac Surg. 2024 Sep;118(3):681-682. doi: 10.1016/j.athoracsur.2024.03.011. Epub 2024 Mar 18. Ann Thorac Surg. 2024. PMID: 38508510 No abstract available.
-
A Pathologic Complete Response to Neoadjuvant Chemotherapy and Immunotherapy Followed by Surgery in a Patient With NSCLC.J Thorac Oncol. 2019 May;14(5):e104-e106. doi: 10.1016/j.jtho.2018.12.025. J Thorac Oncol. 2019. PMID: 31027744 No abstract available.
-
Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer.Thorac Surg Clin. 2020 May;30(2):215-220. doi: 10.1016/j.thorsurg.2020.01.001. Thorac Surg Clin. 2020. PMID: 32327180 Review.
-
A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.BMC Pulm Med. 2022 Dec 29;22(1):490. doi: 10.1186/s12890-022-02292-5. BMC Pulm Med. 2022. PMID: 36582007 Free PMC article.
Cited by
-
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.Curr Oncol. 2024 Aug 30;31(9):5121-5139. doi: 10.3390/curroncol31090379. Curr Oncol. 2024. PMID: 39330007 Free PMC article. Review.
-
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting.Curr Oncol. 2025 Feb 14;32(2):110. doi: 10.3390/curroncol32020110. Curr Oncol. 2025. PMID: 39996910 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
